X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12) 12
article (10) 10
gastroenterology and hepatology (8) 8
humans (8) 8
gastroenterology & hepatology (7) 7
hepatocellular carcinoma (6) 6
mice (6) 6
animals (5) 5
liver cancer (5) 5
male (5) 5
apoptosis (4) 4
cancer (4) 4
fatty liver (4) 4
liver diseases (4) 4
steatosis (4) 4
aged (3) 3
breast-cancer (3) 3
carcinoma, hepatocellular - pathology (3) 3
digestive system diseases (3) 3
fatty liver-disease (3) 3
female (3) 3
fibrosis (3) 3
gene expression (3) 3
health aspects (3) 3
liver (3) 3
liver neoplasms - pathology (3) 3
middle aged (3) 3
multidisciplinary sciences (3) 3
non-alcoholic fatty liver disease (3) 3
rodents (3) 3
united-states (3) 3
adult (2) 2
biomarkers (2) 2
cancer-cells (2) 2
carcinoma, hepatocellular - enzymology (2) 2
carcinoma, hepatocellular - etiology (2) 2
cell line, tumor (2) 2
confidence intervals (2) 2
diagnosis (2) 2
expression (2) 2
factor-beta (2) 2
farnesoid x receptor (2) 2
growth (2) 2
hcc (2) 2
hepatitis b (2) 2
hepatocytes (2) 2
hepatoma (2) 2
liver neoplasms - enzymology (2) 2
liver neoplasms - etiology (2) 2
liver neoplasms, experimental - drug therapy (2) 2
liver transplantation (2) 2
medicine (2) 2
mice, nude (2) 2
non-alcoholic steatohepatitis (2) 2
research (2) 2
retrospective studies (2) 2
risk factors (2) 2
science (2) 2
steatohepatitis (2) 2
sulf1 (2) 2
sulf2 (2) 2
sulfatase 1 (2) 2
sulfotransferases - metabolism (2) 2
surgery (2) 2
survival (2) 2
syngeneic grafts (2) 2
transfection (2) 2
transplantation (2) 2
[sdv.can]life sciences [q-bio]/cancer (1) 1
abridged index medicus (1) 1
acid (1) 1
activation (1) 1
age distribution (1) 1
akt kinase (1) 1
alcoholics (1) 1
alpha-fetoprotein (1) 1
alpha-fetoproteins - metabolism (1) 1
american association (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - pharmacology (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
animal models (1) 1
animal-model (1) 1
anthracyclines (1) 1
antiangiogenics (1) 1
antibiotics, antineoplastic - administration & dosage (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
apoptosis - drug effects (1) 1
autoimmune pancreatitis (1) 1
b-virus infection (1) 1
benzenesulfonates - pharmacology (1) 1
benzenesulfonates - therapeutic use (1) 1
beta catenin (1) 1
beta-receptor (1) 1
bile duct neoplasms - diagnosis (1) 1
bile duct neoplasms - immunology (1) 1
bile duct neoplasms - mortality (1) 1
bile ducts, intrahepatic (1) 1
biological markers (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Liver International, ISSN 1478-3223, 01/2017, Volume 37, Issue S1, pp. 97 - 103
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic... 
non‐alcoholic steatohepatitis (NASH) | peroxisome proliferator‐activator receptor (PPAR) agonists | farnesoid X receptor (FXR) | non‐alcoholic fatty liver disease (NAFLD) | ROS (reactive oxygen species) | glucagon‐like peptide (GLP‐1) agonist | non-alcoholic fatty liver disease (NAFLD) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | non-alcoholic steatohepatitis (NASH) | VITAMIN-E | ACID | RANDOMIZED-TRIALS | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | WEIGHT-LOSS | GLUCAGON-LIKE PEPTIDE-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | PENTOXIFYLLINE | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article
Journal Article
Liver Transplantation, ISSN 1527-6465, 05/2015, Volume 21, Issue 5, pp. 599 - 606
Journal Article
Hepatology, ISSN 0270-9139, 11/2010, Volume 52, Issue 5, pp. 1680 - 1689
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 02/2017, Volume 77, Issue 3, pp. 632 - 645
Existing antiangiogenic approaches to treat metastatic hepatocellular carcinoma (HCC) are weakly effectual, prompting further study of tumor angiogenesis in... 
CANCER-CELLS | SURVIVAL | ACTIVATION | FACTOR-BETA | PROTEIN | MICROENVIRONMENT | ONCOLOGY | PATHWAY | FIBROBLAST-GROWTH-FACTOR | HEPARAN-SULFATE | EXPRESSION
Journal Article
Cancer Epidemiology Biomarkers & Prevention, ISSN 1055-9965, 02/2017, Volume 26, Issue 2 Supplement, pp. C76 - C76
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2012, Volume 87, Issue 1, pp. 17 - 24
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 04/2009, Volume 13, Issue 4, pp. 443 - 454
Journal Article